CytomX Therapeutics Total Revenue

As of the most recent data (June 2026), CTMX shows a total revenue of $18M. That compares with $140M in the prior-year period — down 87.0% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CTMX's total revenue is now $18M (was $140M) — a 87.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether CytomX Therapeutics is outperforming or lagging.

The Healthcare sector average total revenue is about $110B. CytomX Therapeutics is at $18M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how CTMX stacks up against individual peers as well.

Tracking CTMX's total revenue over time shows whether CytomX Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $18M That compares with $140M in the prior-year period — down 87.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has CytomX Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $18M) with ownership activity and broader fundamentals.